Page 1 of 2: Library: last year it was bosentan........this year?

vijaya47 · Credits: 250 My Scrapbook

can you please provide a list of new drugs which can be expected in this years aipg entrance test?

doctorgirl78 · Credits: 5306 My Scrapbook

for the latest in drugs try out the latest CMDT..........i have gone through the new release tripathi............it only takes the trouble of mentioning the names if at all of the new on scene and wont help you here in particular...

sanjukta · Credits: 100 My Scrapbook

Cardiology/Vascular Diseases

Crestor (rosuvastatin calcium); For the treatment of primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia; AstraZeneca; Approved August 2003
Levitra (vardenafil); For the treatment of erectile dysfunction related to sexual activity in men; Bayer / GlaxoSmithKline; Approved September 2003
Dental/Maxillofacial Surgery

No approvals recorded to date in this area.

Dermatology /Plastic Surgery

Amevive (alefacept); For moderate to severe chronic plaque psoriasis.; Biogen; Approved January 2003
Finacea (azelaic acid) Gel, 15%; Gel formulation for the treatment of rosacea.; Berlex Laboratories,; January 2003
Endocrinology

Aldurazyme (laronidase); For the treatment of Mucopolysaccharidosis I (MPS I) in subjects aged 5 to 65; Genzyme General; Approved May 2003
Fabrazyme (agalsidase beta); For the treatment of Fabry disease in adult patients; Genzyme General; Approved April 2003
Somavert (pegvisomant); Injectable formulation for the treatment of acromegaly; Pharmacia; Approved March 2003
Gastroenterology

Aloxi (palonosetron); For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; MGI Pharma / Helsinn Healthcare; Approved August 2003
Emend (aprepitant); For the treatment of nausea and vomiting associated with chemotherapy; Merck; Approved March 2003
Oxytrol (oxybutynin transdermal system); For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.; Watson Pharmaceuticals; Approved March 2003
Hematology

Bexxar; For the treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma following chemotherapy relapse; Corixa; Approved June 2003
Levitra (vardenafil); For the treatment of erectile dysfunction related to sexual activity in men; Bayer / GlaxoSmithKline; Approved September 2003
Reyataz (atazanavir sulfate); For the treatment of HIV-1 infection in combination with other antiretroviral agents; Bristol-Myers Squibb; Approved July 2003
Zemaira (alpha1-proteinase inhibitor); For the treatment of alpha1-proteinase inhibitor deficiency (Alpha-1) and emphysema; Aventis Behring; Approved July 2003
Immunology/Infectious Diseases

Amevive (alefacept); For moderate to severe chronic plaque psoriasis.; Biogen; Approved January 2003
FluMist ( Influenza Virus Vaccine); For the prevention of disease caused by influenza A and B viruses; MedImmune; Approved June 2003
Fuzeon (enfuvirtide); For the treatment of HIV-1 infection in combination with other antiretroviral agents; Trimeris / Hoffmann-La Roche; Approved March 2003
Reyataz (atazanavir sulfate); For the treatment of HIV-1 infection in combination with other antiretroviral agents; Bristol-Myers Squibb; Approved July 2003
Musculoskeletal

Aldurazyme (laronidase); For the treatment of Mucopolysaccharidosis I (MPS I) in subjects aged 5 to 65; Genzyme General; Approved May 2003
Boniva (ibandronate sodium); For the prevention and treatment of osteoporosis in post-menopausal women; Hoffman La Roche; Approved May 2003
Somavert (pegvisomant); Injectable formulation for the treatment of acromegaly; Pharmacia; Approved March 2003
Velcade (bortezomib); Injectable agent for the treatment of multiple myeloma patients who have received at least two prior therapies.; Millennium Pharmaceuticals; Approved May 2003
Nephrology/Urology

Fabrazyme (agalsidase beta); For the treatment of Fabry disease in adult patients; Genzyme General; Approved April 2003
Oxytrol (oxybutynin transdermal system); For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.; Watson Pharmaceuticals; Approved March 2003
UroXatral (alfuzosin HCl extended-release tablets); For the treatment of of the signs and symptoms of benign prostatic hyperplasia; Sanofi-Synthelabo; Approved June 2003
Neurology

Levitra (vardenafil); For the treatment of erectile dysfunction related to sexual activity in men; Bayer / GlaxoSmithKline; Approved September 2003
Obstetrics/Gynecology

Boniva (ibandronate sodium); For the prevention and treatment of osteoporosis in post-menopausal women; Hoffman La Roche; Approved May 2003
Oncology

Aloxi (palonosetron); For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; MGI Pharma / Helsinn Healthcare; Approved August 2003
Bexxar; For the treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma following chemotherapy relapse; Corixa; Approved June 2003
Emend (aprepitant); For the treatment of nausea and vomiting associated with chemotherapy; Merck; Approved March 2003
Iressa (gefitinib); For the second-line treatment of non-small-cell lung cancer; AstraZeneca; Approved May 2003
UroXatral (alfuzosin HCl extended-release tablets); For the treatment of of the signs and symptoms of benign prostatic hyperplasia; Sanofi-Synthelabo; Approved June 2003
Velcade (bortezomib); Injectable agent for the treatment of multiple myeloma patients who have received at least two prior therapies.; Millennium Pharmaceuticals; Approved May 2003
Ophthalmology

No approvals recorded to date in this area.

Otolaryngology

No approvals recorded to date in this area.

Pediatrics/Neonatology

Aldurazyme (laronidase); For the treatment of Mucopolysaccharidosis I (MPS I) in subjects aged 5 to 65; Genzyme General; Approved May 2003
Pharmacology /Toxicology

No approvals recorded to date in this area.

Psychiatry /Psychology

No approvals recorded to date in this area.

Pulmonary/Respiratory Diseases

Aldurazyme (laronidase); For the treatment of Mucopolysaccharidosis I (MPS I) in subjects aged 5 to 65; Genzyme General; Approved May 2003
Iressa (gefitinib); For the second-line treatment of non-small-cell lung cancer; AstraZeneca; Approved May 2003
Zemaira (alpha1-proteinase inhibitor); For the treatment of alpha1-proteinase inhibitor deficiency (Alpha-1) and emphysema; Aventis Behring; Approved July 2003

Infectious Dieseases
Pyronaridine: substituted 1-aza-acridine and also a substituted 1,5-napthyridine Millennium Pharmaceuticals; Approved Jan 2003
Rheumatology

Boniva (ibandronate sodium); For the prevention and treatment of osteoporosis in post-menopausal women; Hoffman La Roche; Approved May 2003

Bruno · Credits: 44569 My Scrapbook My Reading List 50 Books

I have a gut feeling that you are going to get a OLD drug this time

Mandrax

Baralgan

spiderman · Credits: 502 My Scrapbook

glmedicine · Credits: 316 My Scrapbook

WOW the list of neww drug by sanjukta!! is incredible and SPIDERMAN'S reply to the above mentioned post justifies it.
THANKS for the great compilation

anjula · Credits: 77491 My Scrapbook My Reading List 262569 Books

.. gREAT STUFF .. gOT THIS ANSWER RIGHT . Thanks for the discussion

MUKESH123 · Credits: 77491 My Scrapbook My Reading List 262569 Books

Message Deleted !!!!

Avoid posting irrelevant texts

RxPG_Team · Credits: 19655971 My Scrapbook My Reading List 5 Books

bump!

dr_renu · Credits: 624 My Scrapbook

wow really g8 stuff . ''a must read'' for all pg aspirants

		Sign In New User? Sign Up Sign in to access your control panel and messenger!
				TechZone \| SpiderNevi \| HowTo? \| Scrapbook!